MedTrace Logo

Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis

NCT02978183 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2023-04-10

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy of ST266 ophthalmic drops compared to placebo for the treatment of the signs and symptoms of allergic conjunctivitis.

Conditions

  • Allergic Conjunctivitis

Interventions

BIOLOGICAL

ST266

One (1) drop of 1X ST266 ophthalmic eye drops will be administered to each eye 4 times a day for 8 days.

DRUG

Saline (0.9% NaCl)

One (1) drop of saline ophthalmic eye drops will be administered to each eye 4 times a day for 8 days.

Sponsors & Collaborators

  • Noveome Biotherapeutics, formerly Stemnion

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2017-02-28
Completion
2017-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02978183 on ClinicalTrials.gov